Combination Therapy for Age-Related Macular Degeneration.

Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Study ID
NCT00376701
Phase
PHASE2
Status
Completed

Conditions

  • Age Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary purpose of the study is to investigate whether patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration, receiving triple or double therapy compared to monotherapy with Avastin will reduce the intervention rate with equivalent safety and efficacy.

Key Dates

First listed
Sep 15, 2006
Start date
Sep 30, 2006
Status verified
Sep 2011
Primary completion
Apr 30, 2009
Completion
Apr 30, 2009

Study Design

Enrollment
103 participants (actual)
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Reduced fluence PDT plus intravitreal Kenalog (2 mg) plus intravitreal Avastin 1.25 mg
  • Experimental: 2
    Reduced fluence PDT plus intravitreal Avastin
  • Experimental: 3
    Intravitreal Avastin and sham reduced fluence PDT

Primary Outcome Measure

To investigate whether patients with CNV secondary to AMD, receiving triple or double therapy compared to monotherapy with Avastin, will reduce the intervention rate with equivalent safety and efficacy. [ Time Frame: 1 year ]

Related Studies